TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22871230

Group type: EXPERIMENTAL
Intervention: Computer metabolic system model for insulin infusion rates; short-term trials (24 hours) on 8 infants.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Computer metabolic system model for insulin infusion rates; long-term trials on 22 infants.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin infusions determined by sliding scales and clinician intuition; retrospective cohort of 21 patients.
Number of subjects: 30
Study: 22871833

Group type: EXPERIMENTAL
Intervention: Diabetic eyes (PGE2 levels)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nondiabetic eyes (PGE2 levels)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diabetic eyes (VEGF levels)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nondiabetic eyes (VEGF levels)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diabetic eyes (other cytokines)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Correlation of PGE2 with IP-10 and VEGF
Number of subjects: 26
Study: 22872673

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22872731

Group type: EXPERIMENTAL
Intervention: Seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: 2010-2011 split TIV
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: 2011-2012 split TIV
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted TIV
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Unadjuvanted subunit TIV
Number of subjects: 1116
Study: 22873533

Group type: EXPERIMENTAL
Intervention: Ventricular assist device (specific device for children)
Number of subjects: 48
Study: 22873637

Group type: EXPERIMENTAL
Intervention: Cocktail sedation (propofol, meperidine, midazolam)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Conventional sedation (meperidine, midazolam)
Number of subjects: 205
Study: 22873940

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety and concern
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CMD-SQ, EQ-5D, SF-12, HVOK, RCS, OHS/OSS questionnaires
Number of subjects: 500
Study: 22874520

Group type: EXPERIMENTAL
Intervention: ART-exposed group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22874599

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 2455

Group type: COMPARATOR
Intervention: Laparotomy/resection
Number of subjects: 2455
Study: 22875136

Group type: EXPERIMENTAL
Intervention: Epiretinal membrane removal surgery
Number of subjects: 52
Study: 22875626

Group type: EXPERIMENTAL
Intervention: Deferasirox (30 mg/kg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deferoxamine (40 mg/kg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of deferasirox and deferoxamine
Number of subjects: 6
Study: 22875627

Group type: EXPERIMENTAL
Intervention: IKZF1 deletions
Number of subjects: 694
Study: 22875883

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ultrasmall superparamagnetic particles of iron oxide (4 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 16
Study: 22877812

Group type: EXPERIMENTAL
Intervention: Elevated CRP levels
Number of subjects: 785
Study: 22877866

Group type: EXPERIMENTAL
Intervention: GCSF-mobilized CD34+ cell therapy
Number of subjects: 17
Study: 22878519

Group type: EXPERIMENTAL
Intervention: BMS-690514 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BMS-690514 200 mg
Number of subjects: 9
Study: 22878551

Group type: EXPERIMENTAL
Intervention: Hypocaloric, isonitrogenous nutrition administered via intravenous infusion of glucose with amino acids over 72 hours (24 hours before to 48 hours after surgery). Glucose provided 50% and amino acids provided 20% of the patient's measured resting energy expenditure.
Number of subjects: 17
Study: 22878784

Group type: EXPERIMENTAL
Intervention: Nocturnal polysomnography with transcutaneous capnography
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 46
Study: 22880942

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (0.3 mg/kg for <6 years, 20 mg or 40 mg tablets for ≥6 years)
Number of subjects: 24
Study: 22882209

Group type: EXPERIMENTAL
Intervention: High serum vascular endothelial growth factor (s-VEGF) levels
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low serum vascular endothelial growth factor (s-VEGF) levels
Number of subjects: 102
Study: 22883224

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1001
Study: 22883549

Group type: EXPERIMENTAL
Intervention: Autograft reinterventions in adults
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Homograft reinterventions in adults
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Autograft reinterventions in pediatric population
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Homograft reinterventions in pediatric population
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Predictors for shorter time to reoperation
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Endocarditis as a reason for reintervention
Number of subjects: 2023
Study: 22883691

Group type: EXPERIMENTAL
Intervention: New research criteria diagnosis combining clinical and biomarker information
Number of subjects: 241

Group type: COMPARATOR
Intervention: Clinical practice diagnosis at baseline using clinical information only (no biomarkers)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Economic model combining evidence from the study, literature, and expert opinion
Number of subjects: 241
Study: 22883740

Group type: EXPERIMENTAL
Intervention: IV treprostinil
Number of subjects: 3518

Group type: COMPARATOR
Intervention: IV epoprostenol
Number of subjects: 3518
Study: 22884544

Group type: EXPERIMENTAL
Intervention: Standard Shoe (SS) with Flat Insole (FI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standard Shoe (SS) with Carbon Fiber Insole (CFI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rocker Sole Shoe (RSS) with Flat Insole (FI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rocker Sole Shoe (RSS) with Carbon Fiber Insole (CFI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 10
Study: 22884685

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 69
Study: 22884788

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0
Study: 22884879

Group type: EXPERIMENTAL
Intervention: rs1083801 within the GRM7 gene (GG genotype)
Number of subjects: 1541
Study: 22885015

Group type: EXPERIMENTAL
Intervention: Focetria (vaccinated group)
Number of subjects: 127522

Group type: COMPARATOR
Intervention: Unvaccinated group (control)
Number of subjects: 127522
Study: 22885330

Group type: EXPERIMENTAL
Intervention: TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48
Number of subjects: 5

Group type: COMPARATOR
Intervention: TMC435 (200 mg once daily) as monotherapy for 5 days
Number of subjects: 5
Study: 22887690

Group type: EXPERIMENTAL
Intervention: 320-row detector computed tomography (CT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional coronary angiography and single-photon emission CT myocardial perfusion imaging (gold standard)
Number of subjects: 208
Study: 22887757

Group type: EXPERIMENTAL
Intervention: Preoperative fasting blood glucose (FBG) screening
Number of subjects: 275
Study: 22888091

Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) reading by pediatric radiologists
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: CXR reading by pediatric radiologists
Number of subjects: 803
Study: 22889943

Group type: EXPERIMENTAL
Intervention: Compliance with anemia targets (Hb 11.0-12.0 g/dl, transferrin saturation ratio ≥20%, ferritin 100-500 ng/ml)
Number of subjects: 598
Study: 22890635

Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Clinical deterioration
Number of subjects: 327
Study: 22891258

Group type: EXPERIMENTAL
Intervention: Lowest third HDL-C level
Number of subjects: 11140
Study: 22892757

Group type: EXPERIMENTAL
Intervention: Visual acuity assessment
Number of subjects: 606
Study: 22892888

Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, during two 24-hour IOP monitoring sessions (S1 and S2) at a 1-week interval.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, for patients not on glaucoma medication.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, for patients on glaucoma medication.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adverse events during monitoring with the contact lens sensor.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reproducibility assessment using Pearson correlations.
Number of subjects: 40
Study: 22892920

Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg, administered orally
Number of subjects: 5
Study: 22892922

Group type: EXPERIMENTAL
Intervention: ΔRESP PP ≥ 10%
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ΔRESP PP adjustment for driving pressure
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ΔRESP PP ≥ 10% in septic shock patients
Number of subjects: 37
Study: 22894138

Group type: EXPERIMENTAL
Intervention: ASUKI Step pedometer intervention
Number of subjects: 2118
Study: 22894607

Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment in mice bearing PDAC xenografts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SP analysis through whole-genome expression profiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro analysis of SP and MP
Number of subjects: 0
Study: 22894827

Group type: EXPERIMENTAL
Intervention: etanercept treatment (25 mg biweekly for 2 weeks)
Number of subjects: 20
Study: 22894884

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus fotemustine
Number of subjects: 86
Study: 22895887

Group type: EXPERIMENTAL
Intervention: 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy
Number of subjects: 13
Study: 22896000

Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m² twice daily, days 1-14, every 28 days until hematologic response or a maximum of 6 cycles, then days 1-7 every 28 days as maintenance
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m²
Number of subjects: 62
Study: 22897944

Group type: EXPERIMENTAL
Intervention: sunitinib 50 mg/day (4 weeks on treatment, 2 weeks off treatment)
Number of subjects: 61
Study: 22897964

Group type: EXPERIMENTAL
Intervention: i.v. busulfan (BU) 9.6 mg/kg plus melphalan 140 mg/m² (MEL140)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Melphalan 200 mg/m² (MEL200)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: i.v. busulfan plus melphalan
Number of subjects: 153

Group type: COMPARATOR
Intervention: Melphalan 200 mg/m²
Number of subjects: 153
Study: 22898044

Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 28
Study: 22899582

Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 25 mg Days 1-21 with a 7-day break after each cycle
Number of subjects: 18
Study: 22899766

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC) levels
Number of subjects: 823
Study: 22900504

Group type: EXPERIMENTAL
Intervention: UC781 (0.1, 0.25%) gel
Number of subjects: 0
Study: 22901459

Group type: EXPERIMENTAL
Intervention: Canakinumab, 150 mg subcutaneously every 8 weeks for 6 months
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Canakinumab, resumed after flare
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 1
Study: 22901741

Group type: EXPERIMENTAL
Intervention: Proximal UCDs (CPSD or OTCD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Distal UCDs (ASD or ALD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CPSD or OTCD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ALD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CPSD/OTCD
Number of subjects: 103
Study: 22901847

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) treatment with SC injections of leuprolide acetate (LA; Procren 3.75 mg every 28th day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline comparison with healthy age-matched girls
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline comparison with Tanner-matched girls
Number of subjects: 15
Study: 22902483

Group type: EXPERIMENTAL
Intervention: Chemotherapy during pregnancy (median of four cycles, range one to eight); 197 women received chemotherapy, including 178 with anthracycline, 15 with cyclophosphamide, methotrexate, and fluorouracil, and 14 with taxane.
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Chemotherapy in utero
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Infants born before 37 weeks of gestation
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Starting chemotherapy during pregnancy
Number of subjects: 447
Study: 22902761

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy with adenoma detection rates in the lowest quartile (2.0%-7.2%)
Number of subjects: 46835

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy with adenoma detection rates in higher quartiles (above 7.2%)
Number of subjects: 46835

Group type: EXPERIMENTAL
Intervention: Lowest quartile of distal adenoma detection (<7.2%)
Number of subjects: 46835
Study: 22903006

Group type: EXPERIMENTAL
Intervention: Definite PHT (defined by history of complication or clinical findings consistent with PHT)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Possible PHT (one finding present without complication)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Absent PHT (none of the criteria met)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Definite PHT vs Absent PHT
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Definite PHT
Number of subjects: 163
Study: 22903331

Group type: EXPERIMENTAL
Intervention: Iron reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22904181

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT with 250-μg cosyntropin injection
Number of subjects: 1

Group type: COMPARATOR
Intervention: Baseline 18F-FDG PET/CT scan
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Ovarian venous sampling after cosyntropin administration
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Postoperative androgen concentrations
Number of subjects: 1
Study: 22905781

Group type: EXPERIMENTAL
Intervention: Radio messages broadcasted during peak hours (12.00-14.00 and 18.00-23.00)
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Listening to the radio at different times
Number of subjects: 1628
Study: 22906363

Group type: EXPERIMENTAL
Intervention: Initial tidal volume (VT) < 8 mL/kg predicted body weight (PBW)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Initial tidal volume (VT) ≥ 8 mL/kg predicted body weight (PBW)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Initial tidal volume (VT)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Initial tidal volume (VT) ≥ 8 mL/kg PBW
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Post-intubation ALI/ARDS
Number of subjects: 829
Study: 22907176

Group type: EXPERIMENTAL
Intervention: Weight loss intervention over 6 months
Number of subjects: 0
Study: 22909164

Group type: EXPERIMENTAL
Intervention: recombinant human C1 inhibitor (rhC1-INH) 2100 U
Number of subjects: 57
Study: 22909342

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (2 MIU/day for 14 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy with TIL infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of adoptive cell therapy and low-dose IL-2
Number of subjects: 6
Study: 22910104

Group type: EXPERIMENTAL
Intervention: 20 mg of apremilast orally twice daily for 12 weeks
Number of subjects: 10
Study: 22910448

Group type: EXPERIMENTAL
Intervention: Current depressive symptoms
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 823

Group type: COMPARATOR
Intervention: Adjustment for gender and physical activity
Number of subjects: 823
Study: 22910894

Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns of subcorticocortical lesions
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns of multiple lesions
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns (subcorticocortical and multiple lesions)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: New ischemic lesions
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Clinical recurrent stroke
Number of subjects: 353
Study: 22911183

Group type: EXPERIMENTAL
Intervention: Deferasirox 250 mg/d, increased to 500 mg/d after 2 months if new blisters continued to develop
Number of subjects: 10
Study: 22911442

Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization (Y90RE)
Number of subjects: 52
Study: 22911697

Group type: EXPERIMENTAL
Intervention: HCV co-infection
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: HBV co-infection
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: HCV-RNA >800,000 IU/ml
Number of subjects: 3441

Group type: COMPARATOR
Intervention: HCV-RNA undetectable or low
Number of subjects: 3441

Group type: EXPERIMENTAL
Intervention: Interleukin-6, hyaluronic acid, FIB-4 hepatic fibrosis index
Number of subjects: 3441
Study: 22911730

Group type: EXPERIMENTAL
Intervention: Bezafibrate (BF) at a dose of 400 mg daily for 12 weeks, followed by 800 mg daily for another 12 weeks.
Number of subjects: 10
Study: 22912618

Group type: EXPERIMENTAL
Intervention: tDCS (anodal stimulation to the left DLPFC and cathodal stimulation to the right DLPFC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 22913682

Group type: EXPERIMENTAL
Intervention: High-titer anti-interferon-γ autoantibodies
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Neutralizing anti-interferon-γ autoantibodies
Number of subjects: 203
Study: 22913891

Group type: EXPERIMENTAL
Intervention: Exenatide 10-μg BID
Number of subjects: 2067
Study: 22913906

Group type: EXPERIMENTAL
Intervention: LAP-BAND AP® System (LBAP)
Number of subjects: 517
Study: 22913907

Group type: EXPERIMENTAL
Intervention: Cyclosporine (100-mg capsule)
Number of subjects: 24
Study: 22915450

Group type: EXPERIMENTAL
Intervention: Vorinostat (SAHA); individualized dose escalation; specific dosage and duration not provided.
Number of subjects: 0
Study: 22915641

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg/d for 21 days; 28-day cycle) and Azacitidine (75 mg/m(2)/d for 5 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lenalidomide and Azacitidine combination
Number of subjects: 36
Study: 22915649

Group type: EXPERIMENTAL
Intervention: Rozrolimupab (75 to 300 μg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rozrolimupab (300 μg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rozrolimupab
Number of subjects: 61
Study: 22915656

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin with fluoropyrimidine)
Number of subjects: 2246
Study: 22916254

Group type: EXPERIMENTAL
Intervention: Minor allele homozygotes for rs7903146 in healthy young males
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Carriers of the minor allele for rs7903146 in healthy elderly persons
Number of subjects: 218

Group type: COMPARATOR
Intervention: rs7903146 in MetS patients
Number of subjects: 218
Study: 22917457

Group type: EXPERIMENTAL
Intervention: Formalized data feedback
Number of subjects: 1183
Study: 22917945

Group type: COMPARATOR
Intervention: Control group participation
Number of subjects: 60
Study: 22920044

Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy (GPIP) for high attachment anxiety participants
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group Psychodynamic Interpersonal Psychotherapy (GPIP) for low attachment anxiety participants
Number of subjects: 102
Study: 22920644

Group type: EXPERIMENTAL
Intervention: Bortezomib with dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of novel agents with high cut-off hemodialysis membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment for MCN (urgent symptomatic measures and chemotherapy)
Number of subjects: 0
Study: 22920685

Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 20 Gy (n=6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 40 Gy (n=3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 60 Gy (n=3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 80 Gy (n=3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation
Number of subjects: 15
Study: 22921474

Group type: EXPERIMENTAL
Intervention: Dronabinol 30mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dronabinol 60mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dronabinol 120mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 22922469

Group type: EXPERIMENTAL
Intervention: CMS 2 group (n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CMS 1 group (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lowlanders (control group)
Number of subjects: 25
Study: 22922531

Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg IV q14 days (28-day cycles) until disease progression or prohibitive toxicity
Number of subjects: 49
Study: 22922703

Group type: EXPERIMENTAL
Intervention: Frontal Behavioral Inventory (FBI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory (NPI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zarit Burden Inventory (ZBI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mattis Dementia Rating Scale (MDRS)
Number of subjects: 41
Study: 22923433

Group type: EXPERIMENTAL
Intervention: Everolimus (mTOR inhibitor)
Number of subjects: 110

Group type: COMPARATOR
Intervention: TSC1 mutation
Number of subjects: 110
Study: 22923666

Group type: EXPERIMENTAL
Intervention: Bihormonal bionic endocrine pancreas
Number of subjects: 6
Study: 22924125

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 442